Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
Subtype terms (16)
More specific conditions that are subtypes of Cardiomyopathies in the MeSH hierarchy.
- Arrhythmogenic Right Ventricular Dysplasia
5 drugs (2 approved, 3 experimental)
- Cardiomyopathy, Alcoholic
1 drug approved
- Cardiomyopathy, Dilated
63 drugs (36 approved, 27 experimental)
- Cardiomyopathy, Hypertrophic
38 drugs (24 approved, 14 experimental)
- Cardiomyopathy, Restrictive
- Chagas Cardiomyopathy
9 drugs (8 approved, 1 experimental)
- Diabetic Cardiomyopathies
7 drugs (2 approved, 5 experimental)
- Endocardial Fibroelastosis
3 drugs (2 approved, 1 experimental)
- Endomyocardial Fibrosis
20 drugs (14 approved, 6 experimental)
- Glycogen Storage Disease Type IIb
1 drug experimental
- Kearns-Sayre Syndrome
- Myocardial Reperfusion Injury
28 drugs (22 approved, 6 experimental)
- Myocarditis
16 drugs (15 approved, 1 experimental)
- Peripartum Cardiomyopathy
- Sarcoglycanopathies
1 drug experimental
- Takotsubo Cardiomyopathy
9 drugs (7 approved, 2 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (33)
- vitamin d3
- darbepoetin alfa
- deferoxamine
- prednisone
- diltiazem
- empagliflozin
- erythropoetin beta
- adenosine
- deferiprone
- levosimendan
- nesiritide
- bromocriptine
- atorvastatin
- flecainide
- ranolazine
- spironolactone
- verapamil
- carvedilol
- rivaroxaban
- eplerenone
- metoprolol
- regadenoson
- propafenone
- azathioprine
- milrinone
- bisoprolol
- lisinopril
- amiodarone
- iobenguane (123i)
- mavacamten
- +3 more
Phase 3 trials (29)
- vutrisiran
- enalapril
- hydroxychloroquine
- albumin (Human)
- warfarin
- nebivolol
- nitric oxide
- patisiran
- colchicine
- valsartan
- revusiran
- immune globulin (human)
- mycophenolate
- sotagliflozin
- taurine
- tecarfarin
- allogeneic adipose derived mesenchymal stem cell
- oxygen
- dobutamine
- sacubitril
- prednisolone
- sodium chloride
- efgartigimod
- aficamten
- Eplontersen
- ni006
- ntla-2001
- ion 682884
- nnc6019-0001
Phase 2 trials (40)
- seemore
- 99mtc-rhannexin v-128
- atrial natriuretic peptide
- bone autograft
- tadalafil
- doxycycline
- ethanol
- bone marrow derived mesenchymal stem cells
- ic14
- ursodeoxycholic acid
- metaiodobenzylguanidine
- tideglusib
- pomegranate
- semaglutide
- angiotensin 1-7
- triheptanoin
- collagen
- aav1/serca2a
- allogeneic cardiosphere-derived cells
- umbilical cord mesenchymal stem cells
- cardiac stem cells
- ixmyelocel-t
- mydicar
- autologous skeletal myoblast
- autologous mononuclear stem cell
- autologous mesenchymal stem cells
- wharton's jelly mesenchymal stem cells
- dapagliflozin
- genistein
- interferon beta-1b
- +10 more
Phase 1 trials (18)
Other trials (22)
Organizations
Organization Involved with Phase 4 Indications (74)
- Scios
- Gilead Sciences
- AstraZeneca
- Pfizer
- Cardiovascular Imaging Technologies
- GlaxoSmithKline
- Fundación Pública Andaluza
- Midwest Cardiovascular Research Foundation
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Roma La Sapienza
- Shahid Beheshti University of Medical Sciences
- Huazhong University of Science and Technology
- Aarhus University
- University of Pittsburgh
- American Heart Association
- Aminu Kano Teaching Hospital
- University of London
- Dong-A University
- Duke University
- Federal University of Minas Gerais
- Guangxi Medical University
- Harbin Medical University
- Medical University of Warsaw
- Monash University
- Nagoya University
- Nanjing University
- Ohio State University
- Ospedale Microcitemico
- Shandong Provincial Hospital
- Shanxi Medical University
- +44 more
Organization Involved with Phase 3 Indications (60)
- ARYx Therapeutics
- Alexion
- Alnylam Pharmaceuticals
- Array BioPharma
- Ethicare GmbH
- Ionis Pharmaceuticals, Inc.
- Mallinckrodt
- MyoKardia, Inc.
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Fundación Cardioinfantil Instituto de Cardiología
- Fundación Cardiovascular de Colombia
- ZonMw: The Netherlands Organisation for Health Research and Development
- University of Pennsylvania
- Maastricht University
- Ain Shams University
- Andalusian Initiative for Advanced Therapies
- Harvard University
- Institut National de la Santé Et de la Recherche Médicale, France
- Masaryk University
- Newcastle University
- Osaka University
- Sanquin
- University of Florence
- University of Groningen
- University of Oslo
- University of Regensburg
- University of Rochester
- University of Seville
- Utrecht University
- Yonsei University
- +30 more
Organization Involved with Phase 2 Indications (95)
- Foldrx
- Daiichi Sankyo
- Advanced Accelerator Applications
- Astellas
- Genzyme
- Novartis
- Bayer
- Celladon Corporation
- Corimmun GmbH
- Cumberland Pharmaceuticals
- Menarini Group
- Mytogen, Inc.
- POM Wonderful LLC
- Vericel Corporation
- Berlin Cures GmbH
- Capricor Inc.
- Cytokinetics
- Genethon
- Promethera Biosciences
- Fundacion Investigacion y Desarrollo
- The Foundation Institute San Raffaele G. Giglio of Cefalù
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- Heidi Moretti, MS, RD
- Dr. Sami Ulus Children's Hospital
- Allegiance Health
- Bambino Gesù Hospital and Research Institute
- Blood Transfusion Centre of Slovenia
- Case Western Reserve University
- Damanhour University
- +65 more
Organization Involved with Phase 1 Indications (19)
- Celltrion
- National Institutes of Health (NIH)
- Medical Research Council
- Hebei University
- Cedars-Sinai Medical Center
- Emory University
- McGill University
- Odessa National Medical University
- Okayama University
- Translational Research Informatics Center, Kobe, Hyogo, Japan
- University of East Anglia
- University of Louisville
- Celerion
- Shonan Tobu Clinic
- Nucleus Network Ltd
- Texas Medical Center
- Evandro Chagas Institute of Clinical Research
- Oswaldo Cruz Foundation
- Neurimmune AG
Organization Involved with Other Experimental Indications (23)
- Guerbet
- Biosense Webster, Inc.
- St. Jude Medical
- The Methodist Hospital System
- Cardiovascular Institute of the South Clinical Research Corporation
- Chung Shan Medical University
- Cornell University
- Hillel Yaffe Medical Center
- NHS Lothian
- Postgraduate Institute of Medical Education and Research
- Texas Heart Institute
- University of Edinburgh
- University of New Mexico
- Tel Aviv University
- University of California, Davis
- University of California, Los Angeles
- University of Campinas
- University of Minnesota
- University of Nantes
- Thoratec
- Ballou Skies
- Yeshiva University
- Rajaie Cardiovascular Medical and Research Center